Avastin 2015 U.S. PROMOTIONAL AUDIT REPORT

Published July 2016 • 26 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Avastin through personal promotion in 2015 and how does this compare to its peer set in the Breast Cancer, Cervical Cancer, Colorectal Cancer, Glioblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, and Renal Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Genentech’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, and Gynecologic Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Avastin throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Avastin in 2015?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 21,600 paid interactions across 5,000 physicians made on behalf of Avastin were carefully examined to support our analysis. In addition, interaction data from 30 peer products (e.g. Abraxane, Afinitor, Alimta, Cyramza, Erbitux, Fareston, Faslodex, Gilotrif, Halaven, Herceptin, Ibrance, Inlyta, Iressa, Kadcyla, Keytruda, Lynparza, Nexavar, Opdivo, Perjeta, Proleukin, Stivarga, Sutent, Tagrisso, Tarceva, Torisel, Vectibix, Votrient, Xalkori, Zaltrap, and Zykadia) was leveraged to provide benchmarking and market insights.